Multiple myeloma in serologic complete remission after autologous stem cell transplantation: Impact of bone marrow plasma cell assessment by conventional morphology on disease progression

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 1084-1087

  Fernández de Larrea, Carlos ^a   Tovar, Natalia ^a   Rozman, María ^a   Rosiñol, Laura ^a   Aróstegui, Juan Ignacio ^a   Cibeira, María Teresa ^a   Rovira, Montserrat ^a   Yagüe, Jordi ^a   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bone marrow aspirate; Complete remission; Myeloma; Plasma cell; Prognosis; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW PLASMA CELL; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL COUNT; CELL STRUCTURE; CLINICAL ARTICLE; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN CELL; MALE; MICROSCOPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PREDICTOR VARIABLE; PROGNOSIS; REMISSION; SEROLOGIC COMPLETE REMISSION; URINE IMMUNOFIXATION; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW EXAMINATION; BUSULFAN; CELL COUNT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 79958708396     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.707     Document Type: Article

References (19)

1. Lahuerta J.J., Mateos M.V., Martínez-López J., et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26:5775-5782.
2. Wang M., Delasalle K., Feng L., et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2010, 45:498-504.
3. van de Velde H.J., Liu X., Chen G., Cakana A., Deraedt W., Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007, 92:1399-1406.
4. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
5. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
6. Chee C.E., Kumar S., Larson D., et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009, 114:2617-2618.
7. Bland J.M., Altman D.G. Survival probabilities (the Kaplan-Meier method). BMJ 1998, 317:1572.
8. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
9. Nückel H., Rebmann V., Dürig J., Dührsen U., Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005, 105:1694-1698.
10. Sarasquete M.E., García-Sanz R., González D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
11. Martinelli G., Terragna C., Zamagni E., et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000, 8:930-934.
12. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
13. San Miguel J.F., Almeida J., Mateo G., et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002, 99:1853-1856.
14. Liu H., Yuan C., Heinerich J., et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma 2008, 49:306-314.
15. Rawstron A.C., Davies F.E., DasGupta R., et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002, 100:3095-3100.
16. Paiva B., Vidriales M.B., Cerveró J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
17. Paiva B., Vidriales M.B., Pérez J.J., et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009, 94:1599-1602.
18. Barlogie B., Tricot G.J., van Rhee F., et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006, 135:158-164.
19. Rovira M., Rosiñol L., Fernández-Avilés F., et al. Is there a curative potential of autologous stem cell transplantation in multiple myeloma? Long-term results from a single-centre series [abstract]. Bone Marrow Transplant 2009, 43:S147. Abstract no. P592.